# Saccharomyces cerevisiae CBS 8239

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/saccharomyces-cerevisiae-cbs-8239
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Fermented/Probiotic
**Also Known As:** CBS 8239, S. cerevisiae CBS 8239, Baker's yeast strain CBS 8239, Brewer's yeast CBS 8239, Clinical S. cerevisiae CBS 8239, Saccharomyces cerevisiae clinical strain CBS 8239

## Overview

Saccharomyces cerevisiae CBS 8239 is a [probiotic](/ingredients/condition/gut-health) yeast strain that supports intestinal barrier function through enhanced tight junction proteins. This strain demonstrates unique barrier-protective properties with minimal translocation across healthy epithelial tissue.

## Health Benefits

• May support [intestinal barrier integrity](/ingredients/condition/gut-health) (preliminary evidence from in vitro studies showing increased transepithelial electrical resistance in Caco-2 cells)
• Demonstrates limited translocation across intact epithelial barriers compared to pathogenic species (in vitro intestinal barrier models)
• Shows low adhesion to intestinal cells (0.6-6.2%), potentially reducing colonization risks (comparative strain studies)
• Lacks invasive properties or pseudohyphal growth seen in pathogenic yeasts (in vitro characterization)
• Note: No human clinical trials exist for CBS 8239; all evidence is from preclinical models

## Mechanism of Action

Saccharomyces cerevisiae CBS 8239 enhances intestinal barrier function by increasing transepithelial electrical resistance in Caco-2 intestinal epithelial cells, indicating strengthened tight junctions. The strain produces bioactive metabolites that support epithelial cell integrity while maintaining low translocation rates across intact intestinal barriers. Unlike pathogenic microorganisms, this [probiotic](/ingredients/condition/gut-health) yeast exhibits controlled adhesion properties that support barrier function without compromising epithelial integrity.

## Clinical Summary

Current evidence for Saccharomyces cerevisiae CBS 8239 is primarily derived from in vitro studies using intestinal cell models. Laboratory studies demonstrate increased transepithelial electrical resistance in Caco-2 cell monolayers, suggesting enhanced barrier function. Intestinal barrier model studies show limited translocation of this strain compared to pathogenic species, indicating good safety profile. However, human clinical trials are needed to confirm these preliminary findings and establish effective dosing protocols.

## Nutritional Profile

Saccharomyces cerevisiae CBS 8239 is a yeast strain with a composition typical of S. cerevisiae species. Macronutrient profile (per 100g dry weight): Protein 40-50g (rich in all essential amino acids, particularly lysine ~5.9g/100g protein, leucine ~7.5g/100g protein, and glutamic acid ~14g/100g protein); Carbohydrates 35-45g (primarily as beta-glucans 25-35% dry weight, mannans 15-20% dry weight forming the cell wall matrix, and trehalose 5-15% as intracellular storage); Fat 4-7g (predominantly unsaturated fatty acids, oleic acid C18:1 and palmitoleic acid C16:1). Micronutrients: B-vitamins present including thiamine (B1) ~10-15mg/100g, riboflavin (B2) ~4-5mg/100g, niacin (B3) ~35-45mg/100g, pyridoxine (B6) ~2-4mg/100g, folate ~1-2mg/100g, and pantothenic acid ~10-20mg/100g; Minerals include zinc ~7-10mg/100g, selenium variable (strain-dependent, typically 0.1-0.5mg/100g), chromium ~0.1-0.4mg/100g, iron ~3-5mg/100g, and magnesium ~50-80mg/100g. Bioactive compounds: Beta-1,3/1,6-glucans ([immunomodulatory](/ingredients/condition/immune-support) activity, estimated 25-35% dry weight); mannan-oligosaccharides ([prebiotic](/ingredients/condition/gut-health) potential); ergosterol (provitamin D2 precursor, ~0.3-0.7% dry weight, converts to vitamin D2 upon UV exposure); coenzyme Q6 (ubiquinone); [glutathione](/ingredients/condition/detox) ~1% dry weight ([antioxidant](/ingredients/condition/antioxidant)). Bioavailability notes: Cell wall beta-glucans require enzymatic processing or disruption for optimal bioavailability; protein digestibility is moderate (~75-85%) due to cell wall encapsulation; B-vitamins are highly bioavailable upon cell lysis; ergosterol bioavailability is limited unless heat-treated or cell walls disrupted. As a probiotic/live form (CBS 8239 specific strain), the viable cell composition is prioritized over nutritional extraction, and nutrient release depends on gastrointestinal processing conditions.

## Dosage & Preparation

No clinically studied dosages exist for CBS 8239 as no human trials have been conducted. Forms, standardization details, and recommended doses are not established in the scientific literature. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Saccharomyces cerevisiae CBS 8239 appears well-tolerated in laboratory studies with minimal epithelial translocation observed. As with other [probiotic](/ingredients/condition/gut-health) yeasts, individuals with compromised [immune system](/ingredients/condition/immune-support)s or central venous catheters should exercise caution. Potential interactions with antifungal medications may reduce probiotic efficacy. Safety during pregnancy and lactation has not been established through clinical studies.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Saccharomyces cerevisiae CBS 8239 specifically. Available research consists of in vitro studies on clinical S. cerevisiae isolates showing they cannot cross intact epithelial barriers and comparative analyses finding no unique virulence factors versus non-clinical strains (no PMIDs provided in source material).

## Historical & Cultural Context

No historical or traditional medicinal uses were identified for CBS 8239 or clinical S. cerevisiae strains specifically. The species S. cerevisiae has been historically used in food production (baking and brewing) rather than in traditional medicine systems.

## Synergistic Combinations

Other probiotic strains, [Prebiotic](/ingredients/condition/gut-health)s (FOS, GOS), L-glutamine, Zinc carnosine, Quercetin

## Frequently Asked Questions

### What makes Saccharomyces cerevisiae CBS 8239 different from other probiotic yeasts?

CBS 8239 demonstrates enhanced intestinal barrier support with increased transepithelial electrical resistance in cell studies. This strain shows particularly low translocation rates across epithelial barriers compared to other microorganisms, suggesting superior safety characteristics.

### How does Saccharomyces cerevisiae CBS 8239 support gut health?

This probiotic yeast strengthens intestinal tight junctions, as evidenced by increased electrical resistance in Caco-2 cell studies. It supports barrier integrity while maintaining minimal translocation across healthy epithelial tissue, promoting protective gut function.

### Is Saccharomyces cerevisiae CBS 8239 safe for daily use?

Laboratory studies show low translocation rates and good epithelial compatibility, suggesting favorable safety characteristics. However, individuals with compromised immunity or central lines should consult healthcare providers, and human safety data remains limited.

### What dosage of Saccharomyces cerevisiae CBS 8239 is recommended?

Optimal dosing has not been established through human clinical trials, as current evidence comes from laboratory cell studies. Dosage recommendations await completion of human studies to determine effective and safe intake levels.

### Can Saccharomyces cerevisiae CBS 8239 be taken with antibiotics?

As a yeast-based probiotic, CBS 8239 is naturally resistant to antibacterial medications, potentially allowing concurrent use. However, antifungal medications may reduce its viability, and specific interaction studies have not been conducted for this strain.

### What does the clinical evidence show about Saccharomyces cerevisiae CBS 8239's ability to maintain intestinal barrier function?

In vitro studies using Caco-2 intestinal cell models demonstrate that S. cerevisiae CBS 8239 increases transepithelial electrical resistance, a key marker of barrier integrity. However, current evidence is primarily preliminary and limited to laboratory settings, meaning human clinical trials are needed to confirm these barrier-protective effects. The strain shows promise for supporting gut barrier health, but efficacy in living subjects requires further investigation.

### Is Saccharomyces cerevisiae CBS 8239 likely to colonize the gut long-term, or does it pass through the digestive system?

S. cerevisiae CBS 8239 exhibits very low adhesion to intestinal cells (0.6–6.2%), suggesting it is unlikely to establish permanent colonization and instead passes through the digestive tract. This low adhesion profile, combined with its limited ability to translocate across intact intestinal barriers in vitro, indicates the strain functions primarily as a transient probiotic rather than a resident colonizer. This transient nature may reduce colonization-related risks while still providing short-term supportive benefits.

### Who should consider using Saccharomyces cerevisiae CBS 8239 instead of bacterial probiotics?

S. cerevisiae CBS 8239 may be particularly suitable for individuals taking antibiotics, since yeast probiotics are not killed by antibacterial medications, or those with severe bacterial dysbiosis who need an alternative to bacterial strains. It may also benefit people sensitive to certain bacterial species or those seeking a non-colonizing probiotic option. However, individuals with yeast sensitivities or immunocompromised conditions should consult healthcare providers before use.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*